Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.75 |
| ▸ | GAA | P10253 | 2/20 | 0.75 |
| ▸ | GFER | P55789 | 1/20 | 0.75 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.53 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.53 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.52 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30565426 | 1.00 | ALDH1A1 (0.75) | ALDH1A1GAAGFERCYP4F2CYP4A11 | |
| SCHEMBL30026686 | 0.86 | ALDH1A1 (0.66) | ALDH1A1GAAGFERCYP4F2CYP4A11 | |
| SCHEMBL3213276 | 0.86 | ALDH1A1 (0.66) | ALDH1A1GAAGFERCYP4F2CYP4A11 | |
| SCHEMBL8151837 | 0.86 | ALDH1A1 (0.66) | ALDH1A1GAAGFERCYP4F2CYP4A11 | |
| SCHEMBL2436585 | 0.86 | GAA (0.76) | ALDH1A1GAAGFERCYP4F2CYP4A11 | |
| SCHEMBL20045098 | 0.86 | ALDH1A1 (0.71) | ALDH1A1GAAGFERCYP4F2CYP4A11 | |
| SCHEMBL287469 | 0.86 | GAA (1.00) | ALDH1A1GAAGFERCYP4F2CYP4A11 | |
| SCHEMBL8147823 | 0.86 | ALDH1A1 (0.71) | ALDH1A1GAAGFERCYP4F2CYP4A11 | |
| Hydrochloric Acid SCHEMBL11216073 | 0.84 | GAA (0.97) | ALDH1A1GAAGFERCYP4F2CYP4A11 | |
| SCHEMBL7247237 | 0.84 | ALDH1A1 (0.69) | ALDH1A1GAAGFERCYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4232431-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY | LHOTSE BIO INC (US) | 2025-08-13 | — | — | EP | disclosed |
| US-20240018102-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY | Lhotse Bio, Inc (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018102-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY | Lhotse Bio, Inc (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018102-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY | Lhotse Bio, Inc (US) | 2024-01-18 | — | — | US | disclosed |
| EP-3573960-B1 | N-{[2-(PIPERIDIN-1-YL)PHENYL](PHENYL)METHYL}-2-(3-OXO-3,4-DIHYDRO-2H-1,4-BENZOXAZIN-7-YL)ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ROR-GAMMA MODULATORS FOR TREATING AUTOIMMUNE DISEASES | GENFIT (FR) | 2023-08-16 | — | — | EP | disclosed |
| EP-3573960-B1 | N-{[2-(PIPERIDIN-1-YL)PHENYL](PHENYL)METHYL}-2-(3-OXO-3,4-DIHYDRO-2H-1,4-BENZOXAZIN-7-YL)ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ROR-GAMMA MODULATORS FOR TREATING AUTOIMMUNE DISEASES | GENFIT (FR) | 2023-08-16 | — | — | EP | disclosed |
| CN-116583501-A | Compounds and compositions for treating conditions associated with LPA receptor activity | 罗特斯生物公司 | 2023-08-11 | — | — | CN | disclosed |
| WO-2022083703-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY | LHOTSE BIO, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| US-11052092-B2 | N-{[2-(piperidin-1-yl)phenyl](phenyl)methyl}-2-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl)acetamide derivatives and related compounds as ROR-gamma modulators for treating autoimmune diseases | GENFIT (FR) | 2021-07-06 | — | — | US | disclosed |
| US-11052092-B2 | N-{[2-(piperidin-1-yl)phenyl](phenyl)methyl}-2-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl)acetamide derivatives and related compounds as ROR-gamma modulators for treating autoimmune diseases | GENFIT (FR) | 2021-07-06 | — | — | US | disclosed |
| WO-2018138362-A1 | N-{[2-(PIPERIDIN-1-YL)PHENYL](PHENYL)METHYL}-2-(3-OXO-3,4-DIHYDRO-2H-1,4-BENZOXA ZIN-7-YL)ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ROR-GAMMA MODULATORS FOR TREATING AUTOIMMUNE DISEASES | GENFIT (FR) | 2018-08-02 | — | — | WO | disclosed |
| US-20140315881-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. | 2014-10-23 | — | — | US | disclosed |
| EP-2736330-A1 | COMPOUNDS AND METHODS | Tempero Pharmaceuticals, Inc. (US) | 2014-06-04 | — | — | EP | disclosed |
| WO-2013019682-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2013-02-07 | — | — | WO | disclosed |
| US-6544989-B2 | Fungicidal, insecticidal, acaricidal, molluscicidal or nematicidal composition | SYNGENTA LIMITED (GB) | 2003-04-08 | — | — | US | disclosed |
| EP-1100798-B1 | BENZAZOLE, BENZOXAZOLE, BENZTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES | SYNGENTA LTD (GB) | 2002-09-18 | — | — | EP | disclosed |
| EP-1100798-A1 | BENZAZOLES: BENZOXAZOLE, BENZTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES | Zeneca Limited (GB) | 2001-05-23 | — | — | EP | disclosed |
| WO-2000006566-A1 | BENZAZOLES: BENZOXAZOLE, BENZTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES | SYNGENTA LIMITED (GB) | 2000-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11052092-B2 | N-{[2-(piperidin-1-yl)phenyl](phenyl)methyl}-2-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl)acetamide derivatives and related compounds as ROR-gamma modulators for treating autoimmune diseases | RORA, RORC, RORB | ALDH1A1 118/4885GAA 839/4885GFER 3887/4885 |
| US-20240018102-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY | LPAR1, LPAR2, LPAR5 | ALDH1A1 1641/4885GAA 563/4885GFER 3369/4885 |
| US-20140315881-A1 | COMPOUNDS AND METHODS | RORC, RORB, RORA | ALDH1A1 820/4885GAA 1822/4885GFER 2159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.